LONDON, Feb 14 (Reuters) - GW Pharmaceuticals Plc has signed up Japan's Otsuka Pharmaceuticals Co. to develop and market pioneering cannabis-based drug Sativex in the United States, the UK company ...

DUBLIN, May 5, 2021 /PRNewswire/ -- Jazz Pharmaceuticals (Nasdaq: JAZZ) today announced the completion of its acquisition of GW Pharmaceuticals plc (Nasdaq: GWPH) ("GW"), a leader in the science, ...

DUBLIN and LONDON, Feb. 3, 2021 /PRNewswire/ — Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and GW Pharmaceuticals plc (Nasdaq: GWPH) today announced the companies have entered into a definitive agreement ...

Jazz Pharmaceuticals, after getting its hands on the industry’s first FDA-approved cannabis-based medicine last February, is angling to keep its crown with a major manufacturing push overseas. Jazz ...

While JAZZ Pharmaceuticals JAZZ may not be a typical cannabis stock, it is the only company to market an FDA-approved drug that contains a purified drug substance derived from marijuana. The company ...

LONDON (Reuters) - An experimental cannabis drug has produced promising results in a small study of children with hard-to-treat epilepsy, sending shares in its British maker GW Pharmaceuticals to an ...

Researchers and pharmaceutical companies have for years banked on the potential of pot to help tackle everything from anxiety to cancer. But there have been no FDA-approved medications derived from ...

Equities.com invites you to watch Legalized: Making Sense of the Marijuana Green Rush our ground-breaking roundtable discussion on the impact of recreational marijuana's legalization in the United ...

The British cannabis pharmaceutical company takes home an award that demonstrates how important cannabis has been to the British economy for over 20 years—but also how much it so far has been reserved ...

GW Pharmaceuticals PLC- ADR GWPH announced Sunday that two of its medicines have been recommended by the U.K.’s National Institute for Health and Care Excellence to receive routine reimbursement from ...

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) has agreed to acquire GW Pharmaceuticals plc (Nasdaq: GWPH), maker of the first cannabis-based epilepsy drug, in a $7.2 billion cash-and-stock deal, the ...